ea0081oc4.3 | Oral Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022
Fleseriu Maria
, Molitch Mark E
, Dreval Alexander
, Pokramovich Yulia G
, Bondar Irina
, Poteshkin Yury E
, Macut Djuro P
, Obermayer-Pietsch Barbara
, Gilgun-Sherki Yossi
, Haviv Asi
, Biermasz Nienke
, Melmed Shlomo
, Strasburger Christian J
Background: Oral octreotide capsules (OOC) are a treatment option for patients with acromegaly in the United States. The MPOWERED trial (NCT02685709) showed that OOC were noninferior to injectable somatostatin receptor ligands (iSRLs; octreotide or lanreotide) in maintenance of biochemical control in patients previously responding to both treatments, as well as demonstrated improvements in patient-reported outcomes among patients receiving OOC.Objective:...